Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

563.25INR
6:24am EDT
Price Change (% chg)

Rs0.75 (+0.13%)
Prev Close
Rs562.50
Open
Rs564.05
Day's High
Rs569.90
Day's Low
Rs560.50
Volume
533,494
Avg. Vol
1,280,224
52-wk High
Rs569.90
52-wk Low
Rs253.65

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.71
Market Cap (Mil.): Rs238,507.50
Shares Outstanding (Mil.): 424.01
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 35.59 35.92
EPS (TTM): -28.64 -- --
ROI: -- 18.98 18.26
ROE: -- 19.75 19.14
Search Stocks

Drugmaker Novartis to eke out more cost savings to lift margins

ZURICH - Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.

17 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

India caps prices of 108 more medicines; drugmakers to take hit

MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

27 Jun 2014

India's Ranbaxy gets FDA approval for Novartis's Diovan generic

WASHINGTON/MUMBAI - India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

27 Jun 2014

UPDATE 2-India's Ranbaxy gets FDA approval for Novartis's Diovan generic

* Drug could add about $200 mln to Ranbaxy sales - analyst

27 Jun 2014

India's Ranbaxy gains; U.S. drug regulator approves generic version of Novartis drug

MUMBAI - India's Ranbaxy Laboratories rose 5.8 percent in early trading after the U.S. Food and Drug Administration said on Thursday it had approved the company's generic version of Novartis AG's blood pressure drug Diovan.

26 Jun 2014

FDA approves Ranbaxy's generic version of Novartis's Diovan

June 26 - The U.S. Food and Drug Administration said on Thursday it has approved Ranbaxy Laboratories Ltd's generic version of Novartis AG's blood pressure drug Diovan.

26 Jun 2014

INDIA PRESS-Ranbaxy's Gurgaon unit might get to sell drugs in U.S.-Business Standard

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

11 Jun 2014

Europeans, U.S. differ over safety of Ranbaxy facility

- European regulators said on Thursday they have completed their assessment of drug manufacturing violations at Ranbaxy Laboratories Ltd's facility in Toansa, India, and although deficiencies were found, they pose no risk to public health.

05 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: BuySellSignals Research
$5.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks